Inhaled methoxyflurane (Penthrox®) versus placebo for injury-associated analgesia in children-the MAGPIE trial (MEOF-002): study protocol for a randomised controlled trial

Stuart Hartshorn, Michael J Barrett, Mark D Lyttle, Sue Anne Yee, Alan T Irvine, in collaboration with Paediatric Emergency Research in the UK and Ireland (PERUKI), Stuart Hartshorn, Michael J Barrett, Mark D Lyttle, Sue Anne Yee, Alan T Irvine, in collaboration with Paediatric Emergency Research in the UK and Ireland (PERUKI)

Abstract

Background: Pain from injuries is one of the commonest symptoms in children attending emergency departments (EDs), and this is often inadequately treated in both the pre-hospital and ED settings, in part due to challenges of continual assessment and availability of easily administered analgesic options. Pain practices are therefore a key research priority, including within the field of paediatric emergency medicine. Methoxyflurane, delivered via a self-administered Penthrox® inhaler, belongs to the fluorinated hydrocarbon group of volatile anaesthetics and is unique among the group in having analgesic properties at low doses. Despite over 30 years of clinical acute analgesia use, and a large volume of evidence supporting its safety and efficacy, there is a paucity of randomised controlled trial data for Penthrox®.

Methods: This is an international multi-centre randomised, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of methoxyflurane delivered via the Penthrox® inhaler for the management of moderate to severe acute traumatic pain in children and young people aged 6-17 years. Following written informed consent, eligible participants are randomised to self-administer either inhaled methoxyflurane (maximum dose of 2 × 3 ml) or normal saline placebo (maximum dose 2 × 5 ml). Patients, treating clinicians and research nurses are blinded to the treatment. The primary outcome is the change in pain intensity at 15 min after the commencement of treatment, as measured by the Visual Analogue Scale (VAS) or the Wong-Baker FACES® Pain Rating scale, with the latter converted to VAS values. Secondary outcome measures include the number and proportion of responders who achieve a 30% reduction in VAS score compared to baseline, rescue medication requested, time and number of inhalations to first pain relief, global medication performance assessment by the patient, clinician and research nurse, and evaluation of adverse events experienced during treatment and during the subsequent 14 ± 2 days. The primary analysis will be by intention to treat. The total sample size is 110 randomised and treated patients per treatment arm.

Discussion: The Methoxyflurane AnalGesia for Paediatric InjuriEs (MAGPIE) trial will provide efficacy and safety data for methoxyflurane administered via the Penthrox® inhaler, in children and adolescents who present to EDs with moderate to severe injury-related pain.

Trial registration: EudraCT, 2016-004290-41 . Registered on 11 April 2017. ClinicalTrials.gov, NCT03215056 . Registered on 12 July 2017.

Keywords: Analgesia; Injury; Methoxyflurane; Paediatric; Pain; Penthrox®; Randomised trial; Trauma.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
MAGPIE trial flowchart. ED emergency department, MAGPIE Methoxyflurane AnalGesia for Paediatric InjuriEs
Fig. 2
Fig. 2
MAGPIE trial schedule of trial events. MAGPIE Methoxyflurane AnalGesia for Paediatric InjuriEs, UMSS University of Michigan Sedation Scale, VAS Visual Analogue Scale, WBF-PRS Wong-Baker FACES® Pain Rating scale
Fig. 3
Fig. 3
The Penthrox® inhaler

References

    1. Cordell WH, Keene KK, Giles BK, Jones JB, Jones JH, Brizendine EJ. The high prevalence of pain in emergency medical care. Am J Emerg Med. 2002;20(3):165–169. doi: 10.1053/ajem.2002.32643.
    1. Lerner EB, Dayan PS, Brown K, Fuchs S, Leonard J, Borgialli D, et al. Characteristics of the pediatric patients treated by the Pediatric Emergency Care Applied Research Network’s affiliated EMS agencies. Prehospital Emergency Care. 2014;18(1):52–59. doi: 10.3109/10903127.2013.836262.
    1. Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J. Acute pain management: scientific evidence, fourth edition, 2015. Med J Aust. 2016;204(8):315–317. doi: 10.5694/mja16.00133.
    1. Fein JA, Zempsky WT, Cravero JP. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics. 2012;130(5):e1391–e1405. doi: 10.1542/peds.2012-2536.
    1. The College of Emergency Medicine Clinical Audits 2011–12 Pain in Children Executive Summary. The College of Emergency Medicine; 2012. Available at .
    1. National Institute for Health and Care Excellence. Fractures (non-complex): assessment and management. NICE guideline (NG38). 2016. Available at .
    1. Murphy A, McCoy S, O’Reilly K, Fogarty E, Dietz J, Crispino G, et al. A prevalence and management trial of acute pain in children attending emergency departments by ambulance. Prehosp Emerg Care. 2016;20:52–58. doi: 10.3109/10903127.2015.1037478.
    1. Carter D, Sendziuk P, Eliott JA, Braunack-Mayer A. Why is pain still under-treated in the emergency department? Two new hypotheses. Bioethics. 2016;30(3):195–202. doi: 10.1111/bioe.12170.
    1. Hartshorn S, O’Sullivan R, Maconochie IK, Bevan C, Cleugh F, Lyttle MD, et al. Establishing the research priorities of paediatric emergency medicine clinicians in the UK and Ireland. Emerg Med J. 2015;32(11):864–868. doi: 10.1136/emermed-2014-204484.
    1. The Royal College of Emergency Medicine Best Practice Guideline. Management of pain in children (revised July 2017). The Royal College of Emergency. Medicine; 2017. Available at .
    1. Tomlin PJ. Methoxyflurane. Br J Anaesth. 1965;37:706–709. doi: 10.1093/bja/37.9.706.
    1. Dayan AD. Analgesic use of inhaled methoxyflurane: evaluation of its potential nephrotoxicity. Hum Exp Toxicol. 2016;35:91–100. doi: 10.1177/0960327115578743.
    1. Department of Health Therapeutic Goods Administration, Australian Government. “Penthrox (Methoxyflurane)”. Database of Adverse Event Notifications. . Accessed 17 Jan 2019.
    1. Medical Developments International. Penthrox® (methoxyflurane) inhalation product information Version 12. 21 July 2015 [cited 17 Jan 2019] . Accessed 17 Jan 2019.
    1. Grindlay J, Babl FE. Review article: efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting. Emerg Med Australas. 2009;21:4–11.
    1. Coffey F, Wright J, Hartshorn S, Hunt P, Locker T, Mirza K, et al. STOP!: a randomised, double-blind, placebo-controlled trial of the efficacy and safety of methoxyflurane for the treatment of acute pain. Emerg Med J. 2014;31:613–618. doi: 10.1136/emermed-2013-202909.
    1. Chin R, McCaskill M, Browne G, Lam L. A randomized controlled trial of inhaled methoxyflurane pain relief in children with upper limb fracture. J Paediatr Child Health. 2002;38:A13–A14. doi: 10.1046/j.1440-1754.2002.00011.x.
    1. Lyttle MD, O’Sullivan R, Hartshorn S, Bevan C, Cleugh F, Maconochie I, et al. Paediatric Emergency Research in the UK and Ireland (PERUKI): developing a collaborative for multicentre research. Arch Dis Child. 2014;99:602–603. doi: 10.1136/archdischild-2013-304998.
    1. Stinson JN, Kavanagh T, Yamada J, Gill N, Stevens B. Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. Pain. 2016;125:143–157. doi: 10.1016/j.pain.2006.05.006.
    1. Malviya S, Voepel-Lewis T, Tait AR, Merkel S, Tremper K, Naughton N. Depth of sedation in children undergoing computed tomography: validity and reliability of the University of Michigan Sedation Scale (UMSS) Br J Anaesth. 2002;88:241–245. doi: 10.1093/bja/88.2.241.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever